Capsugel Expands Capabilities for Early-Phase Development through Commercial Manufacturing across Multiple Locations in Europe

October 03, 2016

Morristown, N.J., October 3, 2016 – Capsugel, a global leader in delivering high-quality, innovative dosage forms and solutions, today announced that it is expanding the technology platforms and capabilities at its product development and manufacturing sites in Edinburgh, Scotland, and Ploërmel and Strasbourg, France.

“We have taken several of Capsugel’s proprietary technology platforms that have demonstrated advantages with customer product development programs and begun implementing them across multiple sites in our global network,” said Amit Patel, Sr. Vice President and President, Dosage Forms, Capsugel. “This expansion and standardization of our offerings throughout our network allows us to better serve a wider range of customers in more locations, which can help them accelerate speed to market, minimize costs and experience enhanced service levels.” 

Early-Phase Design
Capsugel is installing a proprietary spray-drying unit at its Ploërmel facility later this year to complement the industry-leading technology, expertise and formulation capabilities pioneered at its Bend, Ore. facility in the U.S. The company also has bolstered the Ploërmel facility’s micro-dosing service offering for early-phase feasibility work with the addition of the latest generation of its proprietary Xcelodose® 600S Precision Micro-Dosing System. The system provides expanded capacity and industry-leading powder-in-capsule expertise leveraging the best practices established at Capsugel’s operations in Tampa, Fla., in the U.S. The company also plans to bring both its micro-dosing and spray-drying technologies to its Edinburgh location in 2017.

Formulation R&D in Live Biotherapeutics
Live biotherapeutics, including microbiome, represent a growing area of industry research and development. To meet the increasing number of customers that require this expertise, the company’s Strasbourg R&D facility, with specialized capabilities for the formulation of microbiome products, will open a new containment lab in the fourth quarter.

Manufacturing Expansion
Expanded commercial manufacturing capacity for lipid-based formulations (LBF) using liquid fill hard capsules (LFHC), softgels or lipid multi-particulates is now online at Capsugel’s Edinburgh and Ploërmel sites. Both facilities have expertise in manufacturing LBFs containing high-potency active pharmaceutical ingredients. LBF technologies are a key component in the company’s bioavailability enhancement offering.

Capsugel designs, develops and manufactures a wide range of innovative dosage forms for the biopharmaceutical and consumer health and nutrition industries. Our unique combination of science, engineering, formulation and capsule expertise enables our customers to optimize the bioavailability, targeted delivery and overall performance of their products. We partner with more than 4,000 customers in over 100 countries to create novel, high-quality and customized solutions that align with our customers’ evolving needs and benefit patients and consumers. For more information, visit and follow us on Twitter and LinkedIn.